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incidence and epidemiology
Renal cell carcinoma (RCC) accounts for 2%–3% of all adult
malignancies, representing the seventh most common cancer
in men and the ninth most common cancer in women [1].
Worldwide, there are ∼209 000 new cases and 102 000 deaths
per year. The incidence of all stages of RCC has increased over
the past several years, contributing to a steadily increasing
mortality rate per unit population. Active and passive cigarette
smoking is an established risk factor for RCC as well as
hypertension. However, anti-hypertensive medications such as
diuretics are not independently associated with RCC
development. RCC also appears to be more common in
patients with obesity, end-stage renal failure, acquired renal
cystic disease and tuberous sclerosis.
Approximately 2%–3% of RCC are hereditary and several
autosomal dominant syndromes are described, each with a
distinct genetic basis and phenotype, the most common one
being Von Hippel Lindau (VHL) disease.
diagnosis and pathology/molecular
biology
The proportion of small and incidental renal tumors has
signiﬁcantly increased owing to the widespread use of
abdominal imaging, e.g. ultrasonography, computed
tomography (CT) and magnetic resonance imaging (MRI).
More than 50% of RCCs are currently detected incidentally.
However, a large number of patients with RCC still present
with clinical symptoms, such as ﬂank pain, gross hematuria
and palpable abdominal mass (the classical triad); metastatic
symptoms such as bone pain or lung nodules; or
paraneoplastic syndromes, such as hypercalcemia, unexplained
fever, erythrocytosis or wasting syndromes.
Physical examination alone directs further examinations
especially when symptoms and signs mentioned above are
present. Suspicion of RCC should prompt laboratory
examinations of serum creatinine, hemoglobin, leukocyte
and platelet counts, lactate dehydrogenase and serum-
corrected calcium, in addition to the other symptom-
derived tests [4, B]. Inﬂammatory syndrome tests such as
C-reactive protein (CRP) and erythrocyte sedimentation rate
have been suggested. Some of these tests are
prognosticators for survival and used for risk assessment
(see later).
Most cases of RCC are strongly suspected by imaging.
Diagnosis is usually suggested by ultrasonography and
conﬁrmed by CT scan which allows for the assessment of local
invasiveness, lymph node involvement or other metastases.
MRI may provide additional information in investigating local
advancement, and involvement of venous tumor thrombus,
and in situations where intravenous contrast cannot be used.
For accurate staging of RCC, abdominal and chest CT or
MRI is mandatory [3, A]. Chest CT is the most sensitive
approach for chest staging [3, A]. Unless there is an indication
by clinical or laboratory signs or symptoms, the use of bone
scan or CT (or MRI) of the brain is not recommended for
routine clinical practice [3, A]. Positron emission tomography
is not a standard investigation in the diagnosis and staging of
RCC [1, B].
A renal tumor core biopsy provides the histopathological
conﬁrmation of malignancy with high sensitivity and
speciﬁcity. The diagnosis with a biopsy should especially be
done before the treatment with ablative therapies [3, B]. It is
also indicated in patients with metastatic disease before
commencing systemic treatment [3, B]. The ﬁnal
histopathological diagnosis, classiﬁcation, grading and
evaluation of prognostic factors are based on the nephrectomy
specimen when available.
pathology assessment
Speciﬁc genetic alterations have been identiﬁed in the various
sub-types of RCC (Table 1). Many of these genetic alterations
are also found in the more common sporadic forms of RCC.
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• Clear-cell RCC is the most frequent sub-type of sporadic
RCC in the adult (70%–85%) [2]. The typical histological
feature is the clear aspect of the cells due to glycogen and
lipids in their cytoplasm. They are distributed in tubular and
solid areas with a very prominent capillary stroma. The
multilocular cystic RCC, composed entirely of numerous
cysts lined by clear cells, probably is a variant of low
aggressivity of this sub-type.
• Papillary RCC (7%–15%) [3]. Its name arises from the
distribution of malignant cells around capillary cores
(papillae) in 50%–70% of the tumor [4]. In 73% of cases,
they are type I (cells have scarce cytoplasm), and in 42% they
are type II (eosinophilic cytoplasm). A strong expression of
α-metylacil-CoA racemase is a typical feature.
• Chromophobe RCC (5%–10%). The typical cells are
polygonal with a clear delimitation of the cytoplasmic
membrane (that gives them the appearance of a plant cell).
The pale reticulated cytoplasm (chromophobe) is due to the
presence of abundant cytoplasmic invaginated 150–300-nm
diameter vesicles. LOH 17 associates this tumor with the
Birt–Hogg–Dubé syndrome, c-kit expression is a typical
features of the cells.
• Collecting duct RCC (Bellini tumors). Less than 1% of RCC
are from the medullary distal nephron or Bellini ducts. The
typical morphology of the cells is a high nuclear grade,
eosinophilic cytoplasm, predominant tubular arrangement,
desmoplasia and expression of high-molecular-weight
cytokeratins. Medullary RCC is considered as an
undifferentiated collecting duct carcinoma.
• Some other rare histologies include:
○ Translocation RCC. This rare entity, mainly observed in
children or young adults is characterised by the
translocation of Xp11.2, with the gene-fusion TFE3, or
less frequently the translocation t(6;11)(p21;q12) and
fusion TFEB [5].
○ Mucinous tubular and spindle cell carcinoma.
○ Tubulocystic RCC composed by packed tubules and cysts
lined by cuboidal or hobnail cells with abundant
eosinophilic cytoplasm and large nuclei showing prominent
nucleoli, may represent a subset of papillary RCC.
○ Clear-cell papillary RCC, often associated with end renal
disease.
○ Some RCC still remain unclassiﬁed.
Each of these morphological-genetic RCC sub-types can
correlate with various pathways, such as:
• The hypoxia-inducible pathway (clear cell, papillary type II
through Fumarate gene).
• The mTOR signaling pathway (clear cell and papillary type II).
• The c Met-RAF-MEK-ERK pathway (papillary type I and
translocation RCC).
• The c-kit-RAF-MEK-ERK pathway (chromophobe).
All of these pathways can represent potential targets for
targeted therapies.
staging and risk assessment
staging
The UICC TNM 2009 staging system should be used (Table 2).
Table 1. Gene and chromosomal abnormalities associated with RCC
Histological sub-
types
Chromosomal abnormalities Gene
abnormalities
Clear cell 3p25–26 (34%–56%) of sporadic
carcinomas, 3p14.2 and on 3p12
VHL
Papillary type I Trisomy or tetrasomy 7, trisomy 17
and loss of the chromosome Y
c MET
Papillary type II Trisomy or tetrasomy 7, trisomy 17
and loss of the chromosome Y
Fumarate-
hydratase
Chromophobe Chromosomal loss in 1, 2, 6, 10, 13,
17 and 21
Birt–Hogg–
Dube
Collecting duct
carcinoma
Chromosomal loss in 1q, 6p, 13q,
14, 15, 21q and 22
VHL, Von Hippel Lindau.
Table 2. Staging of RCC (UICC TNM classiﬁcation of malignant tumors,
7th edition, 2009)
T Primary tumor
TX Primary tumor cannot be assessed
T0 No evidence of primary tumor
T1 Tumor ≤7 cm in greatest dimension, limited to the kidney
T1a Tumor ≤4.0 cm
T1b Tumor >4.0 cm but ≤7.0 cm
T2 Tumor >7.0 cm in greatest dimension, limited to the kidney
T2a Tumor >7 cm but ≤10 cm
T2b Tumor >10 cm, limited to the kidney
T3 Tumor extends to major veins or peri-nephric tissues but not
into the ipsi-lateral adrenal gland and not beyond Gerota
fascia
T3a Tumor grossly extends into the renal vein or its segmental
(muscle-containing) branches, or tumor invades peri-renal
and/or renal sinus fat (peri-pelvic) but not beyond Gerota
fascia
T3b Tumor grossly extends into the vena cava below the
diaphragm
T3c Tumor grossly extends into the vena cava above the
diaphragm or invades the wall of the vena cava
T4 Tumor invades beyond Gerota fascia (including contiguous
extension into the ipsi-lateral adrenal gland)
N Regional lymph nodes
NX Regional lymph nodes cannot be assessed
N0 No regional lymph node metastasis
N1 Metastasis in regional lymph node(s)
M Distant metastases
cM0 Clinically no distant metastasis
cM1 Clinically distant metastasis
pM1 Pathologically proven distant metastasis, e.g. needle biopsy
Stage grouping
Stage I T1 N0 M0
Stage II T2 N0 M0
Stage III T3 N0 M0
T1-3 N1 M0
Stage IV T4 Any M0
Any Any M1
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risk assessment
RCC is recognized as having a very variable natural history.
Risk assessment models have been developed to provide
prognostic information for patients and to inform the
eligibility and risk stratiﬁcation designs of clinical trials.
localized disease
Two systems can be used to assess the risk of progression in
localized tumors: the stage size grade and necrosis (SSIGN)
score [6] and the UCLA Integrated Staging System (UISS) [7].
These systems are described in Tables 3 and 4. In SSIGN, risk
points are accumulated as noted in the table below and added
up to provide a risk score.
The SSIGN score compared favorably with the UISS score in
predictive accuracy in a series of patients who had surgically
resected clear-cell RCC. On the other hand, the UISS provides
prognostic predictions for both localized and metastatic disease.
Further prospective data will be available from the current
adjuvant trials for patients with high and intermediate risk RCC.
advanced disease
Prognostic models were ﬁrst built when immunotherapy was the
standard therapy. The Memorial Sloan-Kettering Cancer Center
(MSKCC) or Motzer score was the standard system. The MSKCC
score has now been validated and updated for use in the current
era of targeted therapies as the Heng criteria [8]. Patients are
stratiﬁed according to the presence of six risk factors:
• Karnovsky performance status (PS) <80%.
• Hemoglobin less than lower limit of normal.
• Time from diagnosis to treatment <1 year.
• Corrected calcium above the upper limit of normal.
• Platelets greater than the upper limit of normal.
• Neutrophils greater than the upper limit of normal.
The number of risk factors present is added up and the risk
is stratiﬁed as follows:
Number of
risk
factors
Risk group Median overall
survival (months)
Two-year overall
survival (%)
0 Favorable NR* 75
1–2 Intermediate 27 53
3–6 Poor 8.8 7
*NR, not reported.
Work continues to improve risk score models.
biomarkers
Although there are many potential biomarkers under
investigation, none have yet been validated for general use in
the prognostic or predictive assessment of RCC.
management of local/loco-regional
disease
T1 tumors (<7 cm)
Partial nephrectomy is recommended as the preferred option
in organ conﬁned tumors measuring up to 7 cm (elective
indication) (Table 5). Partial nephrectomy can be performed
via open, laparoscopic or coelioscopic robot-assisted
approaches. In patients with compromised renal function,
solitary kidney or bilateral tumors, partial nephrectomy is also
the standard of care, with no tumor size limitation (imperative
indication). Laparoscopic radical nephrectomy is
recommended if partial nephrectomy is not technically feasible
[9].
Radio frequency or cryo-ablative treatments are alternative
approaches [10], especially in patients with small cortical
tumors, hereditary RCC and multiple bilateral tumors.
Active surveillance is an alternative option in elderly
patients, with substantial co-morbidities or those who have
a short life expectancy and solid renal tumors measuring
<4 cm [11].
T2 tumors (>7 cm)
Laparoscopic radical nephrectomy is the preferred option.
locally advanced RCC (T3 and T4)
Open radical nephrectomy remains the standard of care even
though laparoscopic approach can be considered. Systematic
adrenalectomy or extensive lymph node dissection are not
recommended when abdominal CT shows no evidence of
adrenal or lymph node invasion.
There is no recommended adjuvant treatment, although
many adjuvant trials are ongoing. Inclusion of patients with
localised disease into clinical trials should be encouraged.
Neo-adjuvant approaches are still experimental, especially
for resectable tumors, and should not be proposed outside of
clinical trials. Many studies have demonstrated that such
approaches are relatively safe, with modest median tumor
down-sizing (but more tumor shrinkage in metastatic sites)
and no proven efﬁcacy on disease-free survival.
Table 3. SSIGN score for localized RCC
Feature Score
Pathological T category of
primary tumor (TNM 2002)
pT1a 0
pT1b 2
pT2 3
pT3a-4 4
Regional lymph node status
(TNM 2002)
pNx or pN0 0
pN1 or pN2 2
Tumor size <10 cm 0
≥10 cm 1
Nuclear grade 1 or 2 0
3 1
4 3
Histological tumor necrosis No 0
Yes 1
Scores Group 5-year metastasis-free
survival (%)
0–2 Low risk 97.1
3–5 Intermediate
risk
73.8
≥6 High risk 31.2
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management of metastatic disease
role of surgery
• In the era of immunotherapy, cyto-reductive nephrectomy
was recommended in patients with good PS [I, A] [12].
Whether this recommendation will remain with current
targeted therapies is being investigated in two prospective
trials. In routine practice, cyto-reductive nephrectomy is
recommended in patients with good PS and large primary
tumors, and for patients with a symptomatic primary lesion.
Cyto-reductive nephrectomy is not recommended in patients
with poor PS.
• Metastasectomy can be considered and performed after
multidisciplinary review for select patients with solitary or
easily accessible pulmonary metastases, solitary resectable
intra-abdominal metastases, a long disease-free interval after
nephrectomy or a partial response in metastases to
immunotherapy or targeted therapy. Recent retrospective
and non-randomized studies of patients with metastatic RCC
(mRCC) have demonstrated a prolonged median survival in
those with metachronous lung metastases and an interval of
at least 2 years [13]. Metastasectomy may provide a possible
survival beneﬁt for a select group of patients with lung
metastases only, a long metachronous disease-free interval
and a response to immunotherapy/targeted therapy before
resection.
systemic treatment
Recommendations mainly relate to clear-cell histology, since
most of the pivotal trials have been done in this common
histological sub-type. In addition, recommendation will differ
according to risk stratiﬁcation (see above) (Table 6).
ﬁrst-line treatment for patients with good or intermediate
prognosis (Figure 1)
Because some RCC have very indolent course, a period of
observation before starting treatment should be considered.
Three treatments have demonstrated efﬁcacy in pivotal phase 3:
bevacizumab (combined with interferon-alpha), sunitinib [I,
A] and pazopanib [II, B] [14–16]. All three drugs have been
registered based on improvement of progression-free survival
(PFS) over either interferon-alpha or placebo. Sorafenib [II, B],
Table 5. Recommendations for the treatment of localised and locally
advanced RCC
Level and grade of
recommendations
Partial nephrectomy is recommended for the
treatment of all T1 tumors if negative
margins are obtained and risk of morbidity
is acceptable.
III, C
Laparoscopic radical nephrectomy is the
preferred option for the treatment of organ-
conﬁned RCC (stages T1T2N0N×M0)
when partial nephrectomy is not feasible.
II, B
Routine adrenalectomy and lymph node
dissection are not required for all radical
nephrectomies.
III, C and I, A
Open radical nephrectomy with the goal of
obtaining negative margins is still the
standard of care for locally advanced RCC.
III, C
Ablative treatments are alternative approaches
in elderly patients with small cortical
tumors (≤3 cm), hereditary RCC and
multiple bilateral tumors.
III, C
Active surveillance is an alternative option in
patients ≥75 years, with substantial co-
morbidities and solid renal tumors
measuring <4 cm.
III, C
Table 4. UISS (UCLA Integrated Staging System)
Patient group Prognostic group
T stage Fuhrman’s grade ECOG status Five-year disease-speciﬁc survival (%)
Localised disease (N0, M0) Low risk 1 1–2 0 91.1
Intermediate risk 1 1–2 1 or more 80.4
1 3–4 Any
2 Any Any
3 1 Any
3 2–4 Any
High 3 2–4 1 or more 54.7
4 Any Any
Metastatic disease Low risk N1M0 Any Any 32
N2M0/M1 1–2 0
Intermediate risk N2M0/M1 1–2 1 or more 19.5
3 0, 1 or more
4 0
High N2M0/M1 4 1 or more 0
Risk groups and 5-year disease-speciﬁc survival.
NB: This is taken from the Oxford Oncology Library.
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interferon-alpha (I-D) and interleukin-2 (III-C) are alternative
options when the other drugs cannot be safely given or in very
selected cases. New options, such as tivozanib (based on phase
3 data reported at ASCO 2012 by Motzer et al.) or axitinib
might become available for ﬁrst-line treatment in the near
future.
ﬁrst-line treatment for patients with prognosis
Temsirolimus is currently the only drug with level 1 evidence
of activity in this patient population [I, B] [17]. The pivotal
trial demonstrated the improvement of overall survival
compared with interferon or combination of temsirolimus and
interferon.
Based on subgroup analysis from the pivotal trial as well as
expanded access programs, sunitinib is another reasonable
option in this setting [II, B].
It is clear that, for many prognosis patients, best supportive
care remains the only suitable treatment option.
second-line treatment (Figure 2)
• Evidence for tyrosine kinase inhibitors (TKIs) being active
after cytokines have been demonstrated with sorafenib [I, A],
pazopanib [II, A] and recently axitinib [I, A] [18, 16, 19].
Sunitinib has also demonstrated activity is this setting (III-
A). However, since VEGF-targeted therapy is now the ﬁrst-
line standard of care, the number of patients treated with
cytokines is decreasing.
• After ﬁrst-line treatment with VEGF-targeted therapy, both
everolimus [20] and axitinib [19] are active, and can be
recommended [respectively II, A and I, B]. Both drugs have
shown substantially improved PFS over placebo (everolimus)
or sorafenib (axitinib). Shifting from one TKI to another (i.e.
from sunitinib to sorafenib or vice versa) showed some
activity, in several, mainly retrospective (and thus highly
biased), trials [III, B].
third-line treatment
Further to second line, enrollment into clinical trials is
recommended where possible. In patients already treated with
two TKIs (or a TKI and bevacizumab), everolimus is
recommended [II, A]. In patients previously treated with
VEGF-targeted therapy and mTOR inhibitor, TKI is a possible
treatment [III, B].
Figure 1 First-line treatment of metastatic RCC.
Table 6. Algorithm for systemic treatment in mRCC
Histology and
setting
Risk group Standard Option
Clear-cell ﬁrst
line
Good or
intermediate
risk
Sunitinib Cytokines (including
high dose IL2)
Bevacizumab +
IFN
Sorafenib
Pazopanib
Poor prognosis Temsirolimus Sunitinib
Sorafenib
Clear-cell
second line
Post-cytokines Sorafenib Sunitinib
Pazopanib
Axitinib
Post-TKIs Everolimus Sorafenib
Axitinib
Clear-cell
third line
Post-2 TKIs Everolimus
Non-clear-cell
histology
Temsirolimus
Sunitinib
Sorafenib
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medical treatment of metastatic disease of non-clear-
cell histology
No prospective randomized data are presently available for
patients with non-clear-cell renal cancer. For these patients,
enrollment into speciﬁcally designed clinical trials is
recommended. However, in the absence of such trials,
recommendations can only be based on the results of the
expanded access programs of sunitinib and sorafenib, of small
retrospective studies, and of the subgroup analysis of the
temsirolimus registration trial. These studies suggest that
patients with non-clear-cell histology may beneﬁt from the
treatment with sunitinib, sorafenib or temsirolimus [III, B].
role of radiotherapy and biphosphonates
Radiotherapy has a limited role in the primary management of
renal cancer [21]. However, it is utilized in many different
clinical situations particularly for unresectable local recurrences
and metastatic disease.
• There is no role of radiotherapy in adjuvant or neo-adjuvant
setting (four negative trials) [II, D].
• Radiotherapy can be used to treat unresectable local or
recurrent disease with the aim of improving local control.
For patients in whom surgery is not possible due to the poor
PS or unsuitable clinical condition of the patient,
radiotherapy may be used as an alternative if other local
therapies such as radio-ablation are not appropriate [IV, B].
• Radiotherapy is an effective therapy for palliation of local
and symptomatic metastatic disease or to prevent the
progression of metastatic disease in critical sites: bones, brain
[I, A]. For symptomatic bone metastasis, local radiotherapy
either as a single fraction or fractionated course can provide
symptom relief in up to two-third of cases with complete
symptomatic responses in up to 20%–25% [1, A].
• For the management of spinal cord compression, an
ambulatory status at diagnosis and limited metastatic disease
are favorable factors. In those patients able to undergo
surgery, the use of surgery and radiotherapy was reported to
improve survival and maintenance of ambulation compared
with irradiation alone [1, A].
• In the management of patient with brain metastases, the use
of cortico-steriods can provide effective temporary relief of
cerebral symptoms. Whole-brain radiotherapy between 20
and 30 Gy in 4–10 fractions, respectively, is effective in local
control and may be enhanced with stereotactic cranial
radiotherapy particularly for the subset of patients with a
single unresectable lesion [II, B].
Bisphosphonate therapy with zoledronic acid has been
shown to reduce skeletal related events in patients with bone
metastatis due to mRCC [22] and is recommended for this
patient cohort based on an assessment of expected patient
survival time and probability of deriving symptomatic beneﬁt
[23] [II, A]. Novel agents other than bisphosphonates (e.g.
radium-223 and denosumab) are presently available (or will be
available in the near future), but their speciﬁc use in kidney
cancer is still investigational.
response evaluation and follow-up
There is no evidence that any particular follow-up protocol
inﬂuences the outcome in early RCC. No standard
recommendation can be given for the follow-up in advanced
RCC either.
The follow-up scheme for localized RCC following surgery,
should be dependent on the therapeutic possibilities upon
recurrence. CT scans of thorax and abdomen are routinely
performed, with time intervals dependent on risk factors.
Long-term follow-up is proposed in some institutions, due to
the possibility of late relapse, but its beneﬁt has never been
demonstrated.
During systemic therapy in mRCC patients, 2–4 month
follow-up schemes with CT scan should be advised to
determine response and resistance. Although not perfect,
RECIST criteria remain the best method to assess drug efﬁcacy.
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